These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46 related articles for article (PubMed ID: 17890944)
1. Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. Sanfilippo KM; Luo S; Wang TF; Fiala M; Schoen M; Wildes TM; Mikhael J; Kuderer NM; Calverley DC; Keller J; Thomas T; Carson KR; Gage BF Am J Hematol; 2019 Nov; 94(11):1176-1184. PubMed ID: 31379000 [TBL] [Abstract][Full Text] [Related]
2. Comparison of three risk assessment models for thromboembolism in multiple myeloma patients receiving immunomodulators: a Brazilian historical cohort. da Costa IHF; de Pádua CAM; de Miranda Drummond PL; Silveira LP; Malta JS; Dos Santos RMM; Reis AMM J Thromb Thrombolysis; 2023 Jul; 56(1):147-155. PubMed ID: 37133703 [TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of thromboembolism in multiple myeloma: a systematic review and meta-analysis. An N; Zhang L; Gu L; Tang T; Zhou H; Tian G Transl Cancer Res; 2023 Mar; 12(3):616-623. PubMed ID: 37033347 [TBL] [Abstract][Full Text] [Related]
4. Approach to Contemporary Risk Assessment, Prevention and Management of Thrombotic Complications in Multiple Myeloma. Fotiou D; Dimopoulos MA; Kastritis E Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551701 [TBL] [Abstract][Full Text] [Related]
5. Venous thromboembolism in multiple myeloma is associated with increased mortality. Schoen MW; Carson KR; Luo S; Gage BF; Li A; Afzal A; Sanfilippo KM Res Pract Thromb Haemost; 2020 Oct; 4(7):1203-1210. PubMed ID: 33134785 [TBL] [Abstract][Full Text] [Related]
6. Multiple Myeloma: Cast Nephropathy, VTE, and Neurologic Complications. Sullivan E; Smith LC; Falco AM J Adv Pract Oncol; 2013 Jan; 4(1):37-46. PubMed ID: 25031979 [TBL] [Abstract][Full Text] [Related]
7. Clinical trial of thalidomide combined with radiotherapy in patients with esophageal cancer. Yu JP; Sun SP; Sun ZQ; Ni XC; Wang J; Li Y; Hu LJ; Li DQ World J Gastroenterol; 2014 May; 20(17):5098-103. PubMed ID: 24803825 [TBL] [Abstract][Full Text] [Related]
8. Absence of tissue factor is characteristic of lymphoid malignancies of both T- and B-cell origin. Cesarman-Maus G; Braggio E; Lome-Maldonado C; Morales-Leyte AL; Fonseca R Thromb Res; 2014 Apr; 133(4):606-9. PubMed ID: 24491425 [TBL] [Abstract][Full Text] [Related]
9. Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. Bringhen S; Mateos MV; Zweegman S; Larocca A; Falcone AP; Oriol A; Rossi D; Cavalli M; Wijermans P; Ria R; Offidani M; Lahuerta JJ; Liberati AM; Mina R; Callea V; Schaafsma M; Cerrato C; Marasca R; Franceschini L; Evangelista A; Teruel AI; van der Holt B; Montefusco V; Ciccone G; Boccadoro M; San Miguel J; Sonneveld P; Palumbo A Haematologica; 2013 Jun; 98(6):980-7. PubMed ID: 23445873 [TBL] [Abstract][Full Text] [Related]
10. Thrombosis is associated with inferior survival in multiple myeloma. Kristinsson SY; Pfeiffer RM; Björkholm M; Schulman S; Landgren O Haematologica; 2012 Oct; 97(10):1603-7. PubMed ID: 22511493 [TBL] [Abstract][Full Text] [Related]
12. SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis. Ritchie JP; Ramani VC; Ren Y; Naggi A; Torri G; Casu B; Penco S; Pisano C; Carminati P; Tortoreto M; Zunino F; Vlodavsky I; Sanderson RD; Yang Y Clin Cancer Res; 2011 Mar; 17(6):1382-93. PubMed ID: 21257720 [TBL] [Abstract][Full Text] [Related]
13. Venous thromboembolism and prognosis in cancer. Khorana AA Thromb Res; 2010 Jun; 125(6):490-3. PubMed ID: 20097409 [TBL] [Abstract][Full Text] [Related]
14. Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients. Zangari M; Barlogie B; Cavallo F; Bolejack V; Fink L; Tricot G Blood Coagul Fibrinolysis; 2007 Oct; 18(7):595-8. PubMed ID: 17890944 [TBL] [Abstract][Full Text] [Related]
15. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Minnema MC; Breitkreutz I; Auwerda JJ; van der Holt B; Cremer FW; van Marion AM; Westveer PH; Sonneveld P; Goldschmidt H; Lokhorst HM Leukemia; 2004 Dec; 18(12):2044-6. PubMed ID: 15470485 [No Abstract] [Full Text] [Related]
16. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. Zangari M; Barlogie B; Anaissie E; Saghafifar F; Eddlemon P; Jacobson J; Lee CK; Thertulien R; Talamo G; Thomas T; Van Rhee F; Fassas A; Fink L; Tricot G Br J Haematol; 2004 Sep; 126(5):715-21. PubMed ID: 15327525 [TBL] [Abstract][Full Text] [Related]
17. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism. Talamo GP; Ibrahim S; Claxton D; Tricot GJ; Fink LM; Zangari M Blood Coagul Fibrinolysis; 2009 Jul; 20(5):337-9. PubMed ID: 19367157 [TBL] [Abstract][Full Text] [Related]
18. Thromboembolism with immunomodulatory agents in the treatment of multiple myeloma. Singh A; Gajra A Cardiovasc Hematol Agents Med Chem; 2011 Jan; 9(1):7-13. PubMed ID: 20874693 [TBL] [Abstract][Full Text] [Related]